Core Viewpoint - Biogen (BIIB.US) reported its Q4 2025 earnings and future outlook, indicating that cost-cutting measures are mitigating the impact of declining sales in its multiple sclerosis (MS) business, with 2026 profit projections exceeding Wall Street expectations [1][2] Financial Performance - Q4 2025 total revenue was approximately $2.3 billion, a slight year-over-year decline of 7%, while adjusted EPS was $1.99, both exceeding Wall Street forecasts [1][2] - For the full year 2025, total revenue was $9.891 billion, reflecting a 2% year-over-year increase, with adjusted EPS at $15.28, down 7% year-over-year, but still above analyst expectations [2] Product Performance - Sales of the drugs Skyclarys and Spinraza fell short of analyst expectations, with Spinraza affected by shipping delays outside the U.S. [1] - Leqembi, a new Alzheimer's treatment, generated approximately $134 million in Q4 2025, showing a sequential increase from $121 million in the previous quarter, but still facing growth constraints due to systemic bottlenecks [2][4] Strategic Initiatives - The company is focusing on reducing reliance on its neuroscience portfolio by acquiring Reata to enhance its rare disease offerings and shifting R&D focus towards immunology [3][5] - Cost discipline has been emphasized, with significant job cuts and reductions in spending since the current CEO took office over three years ago [4] Regulatory Developments - The FDA is expected to make a decision on a higher dose of Spinraza by April 2026, which has been approved in Japan and Europe [6] - Biogen is also awaiting key trial data for a new Alzheimer's drug and a lupus treatment, which could further diversify its product pipeline [6]

Core Viewpoint - The importance of pursuing a career in medicine, whether as a clinician or a researcher, is emphasized, highlighting the unique sense of achievement it brings in saving lives and contributing to scientific advancement [1][2]. Group 1: Medical Career Insights - A student expressed concerns about the pressures of being a clinical doctor and the uncertainties in medical research [1]. - The speaker, a member of the Chinese Academy of Engineering, shared personal experiences to illustrate the fulfillment derived from both clinical practice and research [1]. - The transition of China's scientific community from imitation to achieving significant advancements in certain fields is noted as a motivating factor for researchers [1]. Group 2: Immunology and Disease Prevention - The role of immunology in disease prevention, diagnosis, and treatment is highlighted, with a focus on aligning research with clinical needs [2]. - The speaker advocates for the integration of clinical disease treatment demands to drive the development and application of immunology [2]. - The establishment of the "Committee Science Lecture" series aims to promote scientific knowledge and foster a culture of science appreciation in society [2].

Core Insights - In 2025, significant advancements in immunology research were achieved across basic, translational, and clinical domains, particularly in areas such as mechanobiology, immunometabolism, neuroimmunology, and immunosenescence [1] Group 1: Mechanobiology - Research in mechanobiology and immunity has intensified, revealing that immune cells can convert mechanical stimuli into precise immune regulatory information [2] - A team successfully uncoupled the proliferation and differentiation of CAR-T cells using biomechanical signals, establishing a method to produce application-grade CAR-T cells in just 4.5 days, showing enhanced tumor infiltration and persistent anti-tumor effects against various solid tumors [2] - Findings from a collaboration between Mount Sinai and Harvard demonstrated that intestinal cholinergic neurons sense intraluminal pressure changes through the Piezo1 channel, linking mechanical signals to gut motility regulation and offering new therapeutic insights for inflammatory bowel disease [2] - Research from Shanghai Jiao Tong University identified that mechanical signals reshape neutrophil phenotypes to maintain lung tissue homeostasis, establishing pulmonary capillaries as critical sites for neutrophil functional remodeling [2] Group 2: Immunometabolism - The field of immunometabolism has shifted from "metabolic support of immune function" to "metabolic shaping of immune fate and tissue ecology," becoming a central hub connecting tumor microenvironments, immune exhaustion, and treatment responses [4] - A study revealed the dual impact of metabolism on inflammation and tumor immunotherapy, highlighting the role of the enzyme GLO2 in sepsis and age-related inflammation, and proposing targeting tumor cell metabolism to enhance immunogenicity and overcome PD-1 therapy resistance [4] - Research established the critical role of succinate in maintaining CD8+ T cell stemness, improving mitochondrial quality and epigenetic status to support long-term survival and function of stem-like T cells [4] - A study introduced a metabolic reprogramming approach in CAR-T cells to reduce reliance on high-intensity glycolysis, enhancing anti-tumor effects in hypoxic and nutrient-deprived environments [5] Group 3: Neuroimmunology - Research identified a novel type of macrophage in the peripheral nervous system, challenging the long-held belief that microglia do not exist in this area, thus expanding the understanding of immune cell distribution and function [6] - A study revealed the role of specific neural pathways in behavioral changes induced by cancer cachexia, providing insights into the connection between chronic inflammation and depressive symptoms [6] Group 4: Immunosenescence - Research demonstrated that targeted delivery of three nutritional mRNAs to the liver can significantly alleviate age-related immune system decline, presenting a potential strategy to combat immunosenescence [7] - Findings indicated that the aging adaptive immune system loses its ability to respond to new antigens, leading to a shift from immune defense to immune attack, which may accelerate tissue microenvironment deterioration [8] - A model was developed to predict immune age based on the dynamic changes of peripheral immune cells throughout the human lifespan, aiding in early identification of immunosenescence-related risks and personalized immunotherapy [8] Conclusion - Overall, 2025 marked a systematic advancement in immunology, with groundbreaking discoveries in mechanobiology, immunometabolism, neuroimmunology, and immunosenescence, propelling the field into a new phase of deepened mechanisms and translational applications [9]

Core Viewpoint - Eli Lilly (LLY.US) has agreed to acquire Ventyx Biosciences (VTYX.US) for $14 per share in cash, with a total equity value of approximately $1.2 billion, aiming to expand its immunology business [1][1][1] Group 1: Acquisition Details - The acquisition is expected to be completed in the first half of this year and does not include any financing conditions [1][1] - Bank of America Securities is serving as the exclusive financial advisor to Eli Lilly, while Jefferies is the lead financial advisor for Ventyx [1][1] Group 2: Strategic Rationale - Eli Lilly aims to enhance its immunology portfolio, which is identified as a key growth area for the company [1][1] - The company has successfully attracted investor and patient interest in diabetes and obesity treatments, and is looking to further expand its offerings [1][1] Group 3: Current Product Landscape - Eli Lilly currently markets several drugs for inflammatory diseases, including Taltz, although the key patent for Taltz is set to expire in the coming years [1][1] - The company has previously made significant acquisitions, including a $3.2 billion purchase of Morphic Therapeutics for an experimental drug targeting inflammatory bowel disease and a $2.4 billion acquisition of Dice Therapeutics, which develops oral therapies for psoriasis [1][1]

与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者是一家开发口服银屑病疗法的公司。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 据报道，礼来(LLY.US)正就以超过10亿美元的价格收购Ventyx Biosciences(VTYX.US)进行深入谈判，以 拓展其在免疫学领域的业务。截至发稿，Ventyx股价在美股夜盘交易中上涨62.59%，至16.34美元。这 家总部位于圣地亚哥的生物技术公司专注于研发治疗克罗恩病和类风湿性关节炎等炎症性疾病的药物， 按此价格计算，其市值将增加4.339亿美元。Ventyx收购案的报道正值制药行业准备参加在旧金山举行 的摩根大通医疗保健大会之际，该大会历来是并购交易 ...

Core Insights - The 2025 Nobel Prize in Physiology or Medicine was awarded for the discovery of regulatory T cells, which play a crucial role in immunology and have potential applications in treating diseases like cancer and autoimmune disorders [1][5][13] - Despite the excitement surrounding this discovery, there are currently no approved drugs on the market that are based on regulatory T cells [3][4] - The timeline for potential therapies utilizing regulatory T cells is uncertain, with estimates suggesting it could take up to 20 years for effective treatments to emerge [5][16] Industry Trends - Several biotechnology companies founded by the Nobel laureates are focused on developing therapies that target regulatory T cells, but their products are still in early research stages [6] - The overall outlook for cell therapies, aside from CAR-T, is not optimistic, with some companies, like Takeda, halting their investments in cell therapy [7][8] - The advancements in cancer and autoimmune disease treatments over the past 30 years have largely not involved regulatory T cells, with significant breakthroughs coming from other areas of immunology [10][11] Research and Development Challenges - The journey from scientific discovery to practical application is lengthy, and the complexity of diseases may limit the effectiveness of therapies targeting regulatory T cells [16][18] - Potential safety concerns and manufacturing challenges could hinder the development of drugs based on regulatory T cells, as altering their function may lead to severe adverse reactions [18]

Core Viewpoint - Japan has produced three Nobel Prize winners in the field of immunology, highlighting its strong research capabilities despite recent declines in global rankings [12]. Group 1: Key Contributions of Japanese Researchers - Shimon Sakaguchi, the latest Nobel laureate, discovered that removing specific immune cells can activate immune responses, leading to autoimmune diseases [3][5]. - The research on regulatory T cells by Sakaguchi has significant implications for cancer treatment, with Rakuten Medical initiating clinical trials for a new cancer therapy targeting these cells [5]. - The emergence of gene manipulation technologies in the 1970s spurred global interest in immunology, with Japanese researchers making notable contributions [7]. Group 2: Historical Context and Influential Figures - Notable figures in Japanese immunology include Shohei Hayashi, who made groundbreaking discoveries in oxygenase and was considered a strong candidate for the Nobel Prize [9]. - Tadao Takahashi and Tadamitsu Kishimoto are other key scholars who have significantly advanced the field, with Kishimoto's work leading to the development of blockbuster drugs like Actemra [10][11]. - The legacy of these researchers has fostered a robust environment for immunology in Japan, with many students and successors continuing their impactful work [9][10]. Group 3: Current Challenges and Future Directions - Despite its historical strengths, Japan's scientific competitiveness is declining, necessitating policies to nurture talent and translate research into innovation [12][13].

Core Viewpoint - The article announces the launch of the open-access journal "Immunity & Inflammation," focusing on significant scientific issues and advancements in the fields of immunology and inflammation [2][4]. Group 1: Journal Overview - "Immunity & Inflammation" is co-edited by prominent figures in immunology, including Nobel laureates and leading researchers from various countries [2][5]. - The journal aims to bridge foundational insights with medical innovations, publishing high-quality original research, reviews, and highlights across basic, translational, and clinical research [6]. Group 2: Research Focus - The journal particularly welcomes studies exploring the dual nature of inflammation, inflammation-driven diseases, novel anti-inflammatory interventions, and groundbreaking findings in immune regulation [6]. - It encourages interdisciplinary research, including the use of artificial intelligence and digital health technologies, and aims to establish new standards in relevant research and practice areas [6]. Group 3: Editorial Commitment - The journal is committed to maintaining the highest standards of scientific ethics, integrity, transparency, and reproducibility [6][7]. - It invites global scientific communities to collaborate and contribute to making "Immunity & Inflammation" a vibrant and impactful academic platform [7].

Group 1 - The article introduces Professor Song Zhenju, who holds multiple prestigious positions in emergency medicine and clinical research, including Director of the Emergency Department at Fudan University Zhongshan Hospital and Vice President of the same hospital [1] - Professor Song has led numerous national and provincial research projects, published extensively in high-impact journals, and holds multiple patents, indicating a strong research background and contributions to the field [1] Group 2 - The research directions focus on Acute Respiratory Distress Syndrome (ARDS) mechanisms and interventions, organ damage from sepsis, and mechanisms and interventions for acute poisoning [6] Group 3 - Recruitment is open for postdoctoral positions in fields such as Clinical Medicine, Life Sciences, Biology, Biomedical Engineering, and Pharmacy [3] - Candidates must be under 35 years old, have a strong academic background, and have published at least one SCI paper [5] Group 4 - Compensation will follow national and Fudan University standards, with additional rewards for outstanding performance during the contract period [7] Group 5 - Applicants are required to submit a detailed CV, proof of doctoral degree, and 1-3 representative papers [8] - Contact information for applications is provided, with specific instructions for email subject lines [9][10]

Group 1 - Sanofi is acquiring Blueprint Medicines Corp for $9.1 billion in equity value, enhancing its pipeline in rare immune diseases [1][2] - The acquisition price is set at $129 per share, representing a 27% premium over Blueprint's closing price last Friday [1] - Blueprint shareholders will receive a contingent value right (CVR) worth an additional $2 to $4 per share if the BLU-808 drug meets certain development and regulatory milestones [1] Group 2 - This acquisition reflects Sanofi's ambition to establish a leadership position in immunology, following a previous announcement to acquire Dren Bio, Inc. for up to $1.9 billion [1] - Blueprint Medicines has a strong clinical network among specialists and a pipeline that includes several immunotherapy candidates [2] - The total value of the transaction, including potential CVR payments, is approximately $9.5 billion, with Sanofi expecting the deal to close in the third quarter without significant impact on its 2025 financial guidance [2]